60 filings
6-K
EXAI
Exscientia Plc
22 Apr 24
Current report (foreign)
4:13pm
424B5
EXAI
Exscientia Plc
5 Apr 24
Prospectus supplement for primary offering
6:52am
EFFECT
EXAI
Exscientia Plc
5 Apr 24
Notice of effectiveness
12:14am
F-3
EXAI
Exscientia Plc
21 Mar 24
Shelf registration (foreign)
9:19am
S-8
EXAI
Exscientia Plc
21 Mar 24
Registration of securities for employees
8:46am
6-K
39loj3w516
21 Mar 24
Exscientia Business and Financial Update for the Full Year 2023
7:55am
6-K
fz5 mohnm2lrd
13 Feb 24
Current report (foreign)
6:01am
6-K
h1tu 74011aqxaba
9 Nov 23
Current report (foreign)
7:58am
6-K
9o7lu6zaan68juwf
20 Sep 23
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
4:07pm
6-K
gs1gmt 80qlg
10 Aug 23
Current report (foreign)
7:38am
6-K
e72kln wc
29 Jun 23
Exscientia Announces Expansion of its Technology Leadership Team
8:20am
6-K
602lcei zci
24 May 23
Current report (foreign)
7:59am
6-K
stopp
19 May 23
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
4:37pm
6-K
7g2lfaf332ws87z
17 May 23
Current report (foreign)
4:38pm
6-K
0sxjpp dwmv
9 May 23
Current report (foreign)
4:17pm
6-K
6t57 ep5hux8uq274h3
24 Apr 23
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
5:15pm
6-K
3tr4tiu49e oz0u
23 Mar 23
Exscientia Business and Financial Update for the Full Year 2022
7:35am
6-K
oczk60 clf968
15 Nov 22
Current report (foreign)
8:24am